Travere Therapeutics (NASDAQ: TVTX) SVP reports stock sale and new option grant

Rhea-AI Filing Summary

Travere Therapeutics SVP and Chief Accounting Officer Calvin Sandra reported equity awards and a tax-related stock sale. On January 31, 2026, she received 15,180 shares of common stock through vested restricted stock units and an employee stock option for 20,160 shares at an exercise price of $33.095 per share.

On February 3, 2026, she sold 4,333 shares of common stock at $32.12 per share to cover tax withholding from the RSU settlement, a mandated "sell to cover" transaction rather than a discretionary trade. After these transactions, she directly owned 49,080 shares of common stock and 20,160 stock options.

Insider Trade Summary

Net Seller: 4,333 shares ($139,176)

Net Sell 3 txns

Insider Calvin Sandra

Role SVP, CHIEF ACCOUNTING OFFICER

Sold 4,333 shs ($139K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,333	$32.12	$139K
Grant/Award	Employee stock option (right to buy)	20,160	$0.00	--
Grant/Award	Common Stock	15,180	$0.00	--

Holdings After Transaction: Common Stock — 49,080 shares (Direct); Employee stock option (right to buy) — 20,160 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Calvin Sandra

(Last) (First) (Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DRIVE, SUITE 300

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, CHIEF ACCOUNTING OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/31/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/31/2026		A(1)		15,180	A	$0	53,413	D
Common Stock	02/03/2026		S(2)		4,333	D	$32.12	49,080	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee stock option (right to buy)	$33.095	01/31/2026		A		20,160		(3)	01/31/2036	Common Stock	20,160	$0	20,160	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

2. Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

3. One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is Calvin Sandra in relation to Travere Therapeutics (TVTX)?

Calvin Sandra is an officer of Travere Therapeutics, serving as SVP, Chief Accounting Officer. She is a reporting person for insider transactions in the company’s stock, as disclosed in the Form 4 filed under Section 16 of U.S. securities laws.

What stock sale did Calvin Sandra report for Travere Therapeutics (TVTX)?

Calvin Sandra reported selling 4,333 shares of Travere Therapeutics common stock on February 3, 2026 at a price of $32.12 per share. The filing states this transaction was executed to cover tax withholding from vested restricted stock units, not as a discretionary trade.

How many Travere Therapeutics (TVTX) shares does Calvin Sandra own after these transactions?

After the reported transactions, Calvin Sandra directly owned 49,080 shares of Travere Therapeutics common stock. In addition, she held an employee stock option covering 20,160 shares of common stock, providing the right to buy those shares at a fixed exercise price.

What equity awards did Calvin Sandra receive from Travere Therapeutics (TVTX)?

On January 31, 2026, Calvin Sandra received 15,180 shares of common stock through restricted stock units and an employee stock option for 20,160 shares at an exercise price of $33.095. These awards reflect part of her equity-based compensation package.

What is the vesting schedule for Calvin Sandra’s Travere Therapeutics stock options?

The Form 4 states that one-fourth of the option shares vest and become exercisable on the first anniversary of the grant date. The remaining shares then vest in 36 equal monthly installments, creating a multi-year vesting period tied to continued service.

Why was the Travere Therapeutics (TVTX) stock sale described as a "sell to cover"?

The filing explains the 4,333-share sale was required to cover tax withholding from vested restricted stock units. Under the company’s equity incentive plans, the issuer elected to satisfy this obligation through a broker-managed "sell to cover" transaction, not a voluntary share sale.